KLK3 and prostate carcinoma: Currently investigated immunovacines include dendritic cell vaccine with a chimeric protein as a tumor-associated antigen; PSA antigen co-stimulatory molecules delivered in viral vectors; irradiated prostate cancer cell lines; adenovirus/PSA vaccine in men with recurrent cancer after local therapy and with hormone refractory cancer; DNA-based vaccines and adenoviral vector-expressing Herpes virus thymidine kinase, which targets tumor cells and is followed by anti-herpes drug (71).